Abstract

BackgroundThe emAR study was developed to determine variations in the management of socio-sanitary resources, including drugs use, in patients with rheumatoid arthritis (RA) and Spondyloarthritis (Spa).ObjectivesTo evaluate the fulfillment degree...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis
You Song ... Jing Yuan
Journal of Lipid Research | VOL. 52
You Song, et. al.You Song ... Jing Yuan
01 May 2011
Reduction in long‐term disability in patients with rheumatoid arthritis by disease‐modifying antirheumatic drug–based treatment strategies
Catherine A Williams ... Gurkirpal Singh
Arthritis & Rheumatism | VOL. 39
Catherine A Williams, et. al.Catherine A Williams ... Gurkirpal Singh
01 Apr 1996
Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
T Stijnen ... C F Allaart
Arthritis care & research | VOL. 69
T Stijnen, et. al.T Stijnen ... C F Allaart
31 Aug 2017
Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Natalie N Boytsov ... Kim Saverno
Journal of managed care & specialty pharmacy | VOL. 25
Natalie N Boytsov, et. al.Natalie N Boytsov ... Kim Saverno
01 Aug 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers